Showing results (401-410 of 443) with videos related to
Sort By:
Pageof 45
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 22, 2015
Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)Enchi Liu, Johan Luthman, Jesse M Cedarbaum, et al.Clinical Endocrinology|May 13, 2011
Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patientsE F Hensen, M D Siemers, J C Jansen, et al.Archives of Neurology|August 13, 2008
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer diseaseAdam S Fleisher, Rema Raman, Eric R Siemers, et al.Journal for Immunotherapy of Cancer|November 20, 2024
Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumorsMatthew H Taylor, Aung Naing, John Powderly, et al.Plos Computational Biology|September 19, 2009
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activitiesRui-Ru Ji, Heshani de Silva, Yisheng Jin, et al.The Journal of Prevention of Alzheimer'S Disease|February 15, 2025
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's diseaseErika N Cline, Daniel Antwi-Berko, Karen Sundell, et al.Cancer Research|March 24, 2021
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor ModelsJoseph R Campbell, Bryan R McDonald, Paul B Mesko, et al.Journal of Wound Care|June 14, 2021
Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unitKhosrow S Houschyar, Christian Tapking, Mimi R Borrelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trialChristina A Meyers, Jennifer A Smith, Andrea Bezjak, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 22, 2024
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagementDorene M Rentz, Paul S Aisen, Alireza Atri, et al.Pageof 45